在推进医学创新和成果转化改革试点方面，2022年10月，北京出台《北京天坛医院、北京安定医院医学 创新和成果转化改革试点方案》。试点期间，天坛医院、安定医院等7家医院孵化24个试点项目，覆盖 创新医疗（002173）器械、创新药、体外诊断、数字疗法、药械数据平台等医疗科技前沿领域，其中， 3D打印颅骨瓣、干细胞衍生物卒中新疗法药物、精神疾病数字疗法等属于国际首创。试点项目陆续走 通医院科技成果转化各环节。 市政府办公厅9月底正式出台《北京市深化医疗卫生机构医学创新和成果转化改革试点方案》2.0版。方 案明确，在加大试点医院自有资金投入，加速数据要素价值转化，开展职务科技成果单列管理，推动转 化产品优先入院应用及优化决策程序提高决策效率等方面持续深化改革，继续挖掘优质项目，提升转化 效率，稳妥扩大试点医院范围，推动公益性质的慈善捐赠成为医院科技成果转化资金的重要来源，促进 更多医疗科技成果实现转化。 新京报讯（记者张璐）11月18日，北京市人民政府新闻办公室举行《北京市推进科技成果转化落地行动 方案（2025-2027年）》新闻发布会。记者从会上获悉，市卫健委启动研究型病房卓越临床研究计划， 已投入2亿元支持2 ...

Core Insights - Digital therapy is emerging as a new medical intervention method, utilizing software programs and evidence-based medicine to provide health management, disease treatment, and rehabilitation support through technologies like AI, VR, and XR [3][4]. Policy Support and Industry Growth - Since 2022, Hainan has issued over 30 policies to support the development of the digital therapy industry, covering clinical research, product registration, promotion, payment exploration, and management [3]. - By July 2025, the number of digital therapy companies in Hainan is expected to reach 73, with nearly half located in the Hainan Ecological Software Park, which serves as a core engine for the industry's growth [3]. Product Development and Application - Digital therapy products developed by companies like Hainan Yuan Medical Technology Co., Ltd. include cognitive rehabilitation and psychological counseling, utilizing virtual reality to create engaging and effective treatment experiences [3][4]. - The gamified design of these products helps improve patient compliance, transforming the treatment experience from a passive obligation to an active participation [4]. Cost Efficiency - Traditional psychological counseling can be expensive, with hourly fees for specialists ranging from thousands of yuan, while digital therapy products are supported by the Hainan Provincial Health Commission and cost only around 20 yuan per session [4]. - Digital therapy can significantly reduce operational costs by eliminating the need for large physical spaces and additional staff, potentially saving 3 to 4 nursing personnel in a 50-bed ward [5]. Chronic Disease Management - Companies like Hainan Yiduo Cloud Health Industry Co., Ltd. are leveraging digital therapy for chronic disease management, having managed over 193,000 diabetes patients and nearly 500,000 hypertension patients across 12 cities in Hainan by August 2025 [5][6]. - The use of AI management software empowers village doctors to provide effective treatment for chronic diseases, improving the fasting blood sugar compliance rate by an average of 16.6% and the blood pressure compliance rate by 4.9% [6].

Core Insights - The company has successfully transformed from an automotive parts manufacturer to a leading player in the internet gaming industry, capitalizing on China's digital transformation strategy since 2014 [1][2] - In the first half of 2025, the company reported significant growth with revenue reaching 17.2 billion yuan, a year-on-year increase of 85.5%, and net profit soaring to 2.656 billion yuan, up 129.33% [1] Business Segments - The company operates three main business segments: internet gaming, automotive parts manufacturing, and artificial intelligence cloud data, while also exploring cutting-edge fields like AI and brain science [1][2] - The company has made substantial investments in "hard technology" and virtual-interactive fields, including the development of digital therapy products for conditions like ADHD and Alzheimer's [3] Technological Innovations - The company has engaged in the construction of a digital red culture experience space, integrating AR, VR, and AI technologies to enhance cultural education [3] - It has also invested in AI-driven quality inspection robots for various industries, addressing challenges like labor shortages and high energy consumption [4] Global Expansion - Century Games, a subsidiary, has expanded its gaming business globally, covering over 200 countries and regions, and has seen explosive growth through innovative game releases [5][6] - The game "Whiteout Survival" has achieved over 100 million downloads and topped global mobile game revenue charts, significantly contributing to the company's overseas income of 8.958 billion yuan in the first half of 2025 [6] Cultural Initiatives - The company integrates traditional culture into gaming, creating immersive experiences that promote cultural heritage through modern technology [7] - Collaborations with educational institutions have led to the development of games that serve as resources for traditional culture education [7] Social Responsibility - The company has established a sustainable development committee and has made over 30 million yuan in charitable donations, focusing on community service and social responsibility [8][9] - It has initiated various projects aimed at protecting minors and enhancing digital literacy, demonstrating a commitment to social trust and responsibility [9]

Core Insights - The stock of Brain Dynamics Aurora-B (06681) surged over 14%, reaching HKD 8.5 with a trading volume of HKD 311 million [1] Industry Developments - The Minister of Industry and Information Technology, Li Lecheng, emphasized the need to cultivate emerging industries and create new momentum during the 25th China International Industry Fair, focusing on technological innovation and the establishment of new pillar industries [1] - The National Medical Products Administration has approved the first medical device standard for brain-computer interface technology, which will be implemented on January 1, 2026, laying the foundation for the high-quality development of the brain-computer interface medical device industry [1] Company Highlights - Brain Dynamics Aurora's core product is a brain function information management platform software system, recognized as China's first regulatory-approved digital therapy product for cognitive impairment [2] - The company combines brain science with artificial intelligence, offering unique technological advantages such as virtual human technology and AI [2] - As the first company in China to develop a medical-grade digital therapy product for cognitive impairment, Brain Dynamics Aurora holds a first-mover advantage [2] - The core product is included in the provincial medical insurance reimbursement catalog across 30 provinces in China, enhancing product accessibility and market promotion [2] - The company has successfully established cognitive centers in over 120 hospitals in China, including several leading hospitals certified as "National Medical Centers" [2]

Group 1 - The core concept of the article revolves around the innovative digital therapy solutions provided by Yuan Yikang Health Technology Co., Ltd., which utilizes virtual reality to treat phobias and cognitive disorders [1][4] - Yuan Yikang's therapy involves immersive experiences where patients wear headsets to simulate high-altitude environments, gradually increasing their tolerance to heights [2][3] - The company integrates XR (Extended Reality) and AI technology to offer personalized treatment plans, enhancing diagnostic efficiency and resource management in healthcare [3][4] Group 2 - The digital therapy industry in Hainan has gained significant attention, with the province implementing over 30 supportive policies since 2022 to promote the sector [4] - By July 2025, Hainan is expected to host 73 digital therapy companies, with many being leading firms in their respective niches, particularly within the Hainan Eco-Software Park [4] - Yuan Yikang's cognitive function assessment and training software has received multiple certifications, including EU CE and UK MHRA, and is being marketed in Southeast Asia and Europe [4] Group 3 - The potential applications of digital therapy extend beyond phobias, exploring treatments for PTSD, addiction, autism, and cognitive recovery in elderly patients [5]

Core Viewpoint - The stock of Brainstorm Aurora-B (06681) experienced significant volatility, reaching a new high of 13.8 HKD before dropping over 14% in the afternoon, with a total trading range of 32% throughout the day [1] Group 1: Stock Performance - The stock had previously risen for four consecutive trading days, accumulating a total increase of 125% [1] - As of the latest report, the stock was down 14.84%, trading at 10.04 HKD, with a total transaction volume of 1.724 billion HKD [1] Group 2: Market Activity - Starting from September 8, Brainstorm Aurora was officially included in the Hong Kong Stock Connect list [1] - On September 9, the company attracted southbound capital for stock accumulation, with northbound investors holding 2.1124 million shares, representing 1.66% of total shares [1] Group 3: Company Overview - Brainstorm Aurora is the first domestic company to develop medical-grade digital therapy products targeting cognitive impairment [1] - Its core product is the first cognitive impairment digital therapy product in China to receive regulatory approval, with the first registration certificate obtained in September 2018 [1] Group 4: Financial Performance - In the first half of this year, the company reported revenue of 100 million RMB, reflecting a year-on-year increase of 92.82% [1] - The adjusted net loss for the same period was 88.022 million RMB, which is an increase of 11.64% year-on-year [1]

Group 1 - The stock of Brainstorm Cell Therapeutics (06681) reached a new high of 13.8 HKD since its listing, but later saw a decline of over 14%, with an overall trading range of 32% throughout the day [1] - The stock had previously increased for four consecutive trading days, resulting in a cumulative rise of 125% [1] - As of the report, the stock was down 14.84%, trading at 10.04 HKD, with a total transaction volume of 1.724 billion HKD [1] Group 2 - Starting from September 8, Brainstorm Cell Therapeutics was officially included in the Hong Kong Stock Connect list, attracting southbound capital for stock accumulation [1] - By September 12, northbound investors held 2.1124 million shares, accounting for 1.66% of the total shares [1] - The company is the first in China to develop a medical-grade digital therapy product targeting cognitive impairment, with its core product being the first in the country to receive regulatory approval (registered in September 2018) [1] Group 3 - In the first half of this year, the company reported revenue of 100 million HKD, representing a year-on-year increase of 92.82% [1] - The adjusted net loss for the same period was 88.022 million HKD, which is an increase of 11.64% year-on-year [1]

Core Viewpoint - The stock of Brainstorm Cell Therapeutics (06681) experienced a dramatic surge, rising over 83% to reach a new high of 13.78 HKD, driven by its inclusion in the Hong Kong Stock Connect and the scarcity of its position as the first domestic company focused on digital therapies for cognitive disorders [1][2]. Group 1: Stock Performance Metrics - From September 8 to September 15, the stock exhibited an impressive increase of 88.91%, with a volatility of 158.23% and a turnover rate of 30.107%, resulting in a total trading volume of 35.4 billion HKD [2][3]. - The highest price reached was 13.78 HKD, while the lowest was 5.22 HKD, with a total volume of 3.812 billion shares traded during this period [3]. Group 2: Market Dynamics - The significant turnover rate of 30.107% indicates a major shift in the shareholder structure, with nearly one-third of the floating shares changing hands, suggesting a complete overhaul of the previous holding patterns [3]. - The average holding cost for the market has risen to 9.286 HKD, establishing a solid support level for future price movements [3]. Group 3: Trading Behavior Analysis - The K-line patterns revealed a complex interplay between bulls and bears, with four days of price increases but only three days showing positive closing prices, indicating a fierce battle between buying and selling pressures [4][6]. - Despite the apparent selling pressure, the volume of buying (3.572 billion shares) was significantly higher than selling (0.24 billion shares), demonstrating strong underlying demand [7]. Group 4: Investor Composition - Data shows that southbound funds were the primary drivers of this rally, with nearly 944.3 million shares acquired through the Hong Kong Stock Connect within just five days, representing 0.7458% of the total issued shares [8][10]. - In contrast, local brokers like Yao Cai Securities and Bank of China (Hong Kong) showed much smaller increases in holdings, indicating that their activities were more of a follow-up to the main buying momentum [10]. Group 5: Future Outlook - As of September 15, the stock was trading at 10.22 HKD, reflecting a 36.27% increase for the day, with a trading volume of 21.43 billion HKD, suggesting a transition into a new phase of market activity [11]. - The market is currently in a high-level consolidation phase after a rapid price increase, with future price stability dependent on continued inflows from southbound funds and the company's ability to validate its growth potential [11].

Core Viewpoint - The stock of Brainstorm Cell Therapeutics (06681) experienced a dramatic surge, rising over 83% to reach a new high of 13.78 HKD, driven by its inclusion in the Hong Kong Stock Connect and the scarcity of its position as the first domestic company focused on digital therapies for cognitive disorders [1][2]. Group 1: Stock Performance and Market Dynamics - From September 8 to September 15, the stock exhibited an impressive increase of 88.91%, with a volatility of 158.23% and a turnover rate of 30.107%, resulting in a total trading volume of 35.4 billion HKD [1][2]. - The turnover rate of 30.107% indicates a significant shift in shareholding structure, with nearly one-third of the floating shares changing hands, suggesting a complete overhaul of the previous holding patterns [2]. - The average holding cost for the market has risen to 9.286 HKD, establishing a solid support line for future price movements [2]. Group 2: Market Sentiment and Trading Behavior - The K-line pattern during this period showed a paradox where the stock rose for four days but only recorded three bullish candles, indicating a fierce battle between bulls and bears [3][5]. - Despite the apparent selling pressure, the volume of buying was significantly higher, with bullish volume at 3.572 billion shares, which is 14.88 times the bearish volume, indicating strong buying interest [6]. Group 3: Investor Composition and Market Drivers - Southbound funds were identified as the primary drivers of this rally, with nearly 944.3 million shares acquired through the Stock Connect channels within just five days, representing 0.7458% of the total issued shares [7][9]. - In contrast, local brokers like Yao Cai Securities and Bank of China (Hong Kong) showed much smaller increases in holdings, indicating that their activities were more of a follow-up to the main buying momentum [9]. Group 4: Future Outlook - The stock is currently in a high volatility phase following a significant price increase, with ongoing battles between buyers and sellers in the 10.00-11.00 HKD range [10]. - The future price stability will depend on two key factors: the continued inflow of southbound funds and the company's ability to validate its high growth potential to match the new valuation [10].

Group 1 - The market perceives that companies listed on the Hong Kong stock market benefit from being included in the Hong Kong Stock Connect, as it attracts southbound capital and enhances company visibility [1] - Brain动极光-B (06681.HK) experienced a significant price increase, rising by 32% last Friday and peaking at over 80% before a notable pullback, ultimately trading at HKD 10.4, reflecting a nearly 40% increase [1] - Since entering the Hong Kong Stock Connect, Brain动极光-B has seen its stock price nearly double, with a peak increase exceeding 100% within a week [1] Group 2 - Brain动极光 is the first Chinese company to combine brain science with advanced artificial intelligence to develop medical-grade digital therapy products for cognitive impairments [3] - The company's product pipeline addresses a wide range of cognitive impairments caused by vascular diseases, neurodegenerative diseases, mental disorders, and developmental defects in children [3] - In the first half of this year, Brain动极光 reported revenue of RMB 100 million, marking a year-on-year growth of 92.82% [3] Group 3 - Other stocks that entered the Hong Kong Stock Connect on September 8 also experienced significant price increases, such as药捷安康-B (02617.HK) with a cumulative rise of over 220% and映恩生物-B (09606.HK) with a cumulative rise of over 30% [3]